Advertisement
Advertisement
U.S. markets close in 5 hours 43 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Artelo Biosciences, Inc. (ARTL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.9961-0.3539 (-6.61%)
As of 10:12AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.3500
Open5.2300
Bid5.0900 x 800
Ask5.1400 x 800
Day's Range4.9500 - 5.3553
52 Week Range3.6100 - 19.8000
Volume39,891
Avg. Volume314,396
Market Cap14.187M
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-0.3160
Earnings DateNov 11, 2022 - Nov 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARTL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Artelo Biosciences, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    last yearMorningstar
View more
  • GlobeNewswire

    Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

    Recently Published Findings Support Further Development in Anxiety-Related DisordersSOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced publication of pre-clinical results indicating a novel fatty acid binding protein 5 (FABP5) inhibitor from the Company’s FABP in

  • GlobeNewswire

    Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

    CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy $21.3 Million in Cash and Investments as of June 30, 2022 15-for-1 Reverse Stock Split to be Effective August 10, 2022 SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid s

  • GlobeNewswire

    Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

    Initiates Fourth Cohort at a 650-Microgram Dose with Data Expected in Q4 2022SOLANA BEACH, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced the completion of enrollment of the first three cohorts in the Cancer Appetite Recovery Study (CAReS) and the initiation of a fourth co

Advertisement
Advertisement